Skip to main content

Table 5 Crude incidence and 95% CIs of serious infection (n = 21,832)

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Drug therapy Events Total person-years Crude rate (per 100 patient-year) 95% CI
DMARDs 104 5196.02 2.01 1.65–2.42
TNFi ± DMARDs 490 22,736.79 2.16 1.98–2.36
Non-TNF biologic ± DMARDs 173 6936.41 2.49 2.14–2.88
Tofacitinib ± DMARDs 17 474.48 3.67 2.21–5.75
  1. DMARDs Disease-modifying antirheumatic drugs, TNFi Tumor necrosis factor inhibitors